AR076505A1 - Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies - Google Patents

Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies

Info

Publication number
AR076505A1
AR076505A1 ARP100101462A ARP100101462A AR076505A1 AR 076505 A1 AR076505 A1 AR 076505A1 AR P100101462 A ARP100101462 A AR P100101462A AR P100101462 A ARP100101462 A AR P100101462A AR 076505 A1 AR076505 A1 AR 076505A1
Authority
AR
Argentina
Prior art keywords
feet
treatment
alopurinol
hands
cutaneous reaction
Prior art date
Application number
ARP100101462A
Other languages
English (en)
Inventor
Yolanda Rodemer
Original Assignee
Nobera Pharma Sl
Advancell Advanced In Vitro Cell Technologies S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobera Pharma Sl, Advancell Advanced In Vitro Cell Technologies S A filed Critical Nobera Pharma Sl
Publication of AR076505A1 publication Critical patent/AR076505A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

El alopurinol o su sal se administran de manera topica a las zonas afectadas, palmas de las manos y plantas de los pies, preferiblemente en forma de una crema. Reivindicacion 1: Uso de alopurinol o una sal farmacéuticamente aceptable del mismo en la fabricacion de un medicamento para el tratamiento o la prevencion de la reaccion cutánea en manos-pies (RCMP) inducida por terapia con inhibidores multidiana de quinasa (IMQ).
ARP100101462A 2009-04-29 2010-04-30 Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies AR076505A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (1)

Publication Number Publication Date
AR076505A1 true AR076505A1 (es) 2011-06-15

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101462A AR076505A1 (es) 2009-04-29 2010-04-30 Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies

Country Status (23)

Country Link
US (2) US8623878B2 (es)
EP (2) EP2246057A1 (es)
JP (1) JP6007101B2 (es)
KR (1) KR20120049848A (es)
CN (1) CN102421436B (es)
AR (1) AR076505A1 (es)
AU (2) AU2010243594A1 (es)
BR (1) BRPI1011971A2 (es)
CA (1) CA2759085C (es)
DK (1) DK2424538T3 (es)
ES (1) ES2434366T3 (es)
HK (1) HK1168042A1 (es)
HR (1) HRP20131070T1 (es)
IL (1) IL215831A (es)
ME (1) ME01567B (es)
MX (1) MX2011011529A (es)
NZ (1) NZ595901A (es)
PL (1) PL2424538T3 (es)
PT (1) PT2424538E (es)
RS (1) RS53005B (es)
RU (1) RU2543325C2 (es)
SI (1) SI2424538T1 (es)
WO (1) WO2010125143A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508295A (ja) 2009-10-16 2013-03-07 デューク・ユニヴァーシティ 薬物誘発性手足症候群を治療するための組成物および方法
US20140031310A1 (en) * 2011-01-18 2014-01-30 John Maki Pharmaceutical compositions and methods for making and using them
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
EP3782618A4 (en) * 2018-04-16 2022-01-26 OnQuality Pharmaceuticals China Ltd. METHOD OF PREVENTING OR TREATING SIDE EFFECTS OF CANCER THERAPY
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2037672T3 (es) 1987-02-13 1993-07-01 Pharm-Allergan Gmbh Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente.
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
EP1343492B1 (en) 2000-11-22 2006-02-01 Rxkinetix, Inc. Treatment of mucositis
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
DE60232178D1 (de) 2001-08-29 2009-06-10 Pharmakodex Ltd Vorrichtung zur topischen verabreichung
US20030157191A1 (en) 2001-11-29 2003-08-21 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CA2528378A1 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2004110151A1 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20050148910A1 (en) 2003-12-24 2005-07-07 Gregory Skover Apparatus having a skin-contactable element containing an agent
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
PT1796660T (pt) 2004-09-17 2017-02-13 Biomas Ltd Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta
MX2008015266A (es) 2006-06-01 2009-02-10 Nobera Pharma Sl Uso del alopurinol para el tratamiento de la eritrodisestesia palmo-plantar.

Also Published As

Publication number Publication date
CN102421436A (zh) 2012-04-18
IL215831A (en) 2016-02-29
EP2246057A1 (en) 2010-11-03
AU2010243594A1 (en) 2011-11-10
NZ595901A (en) 2013-11-29
RU2543325C2 (ru) 2015-02-27
AU2016228193A1 (en) 2016-11-03
SI2424538T1 (sl) 2013-12-31
WO2010125143A1 (en) 2010-11-04
RU2011148355A (ru) 2013-06-10
ES2434366T3 (es) 2013-12-16
US20100280051A1 (en) 2010-11-04
JP6007101B2 (ja) 2016-10-12
HK1168042A1 (en) 2012-12-21
US8623878B2 (en) 2014-01-07
JP2012525358A (ja) 2012-10-22
CA2759085C (en) 2016-08-16
CN102421436B (zh) 2014-05-07
CA2759085A1 (en) 2010-11-04
US20140080845A1 (en) 2014-03-20
MX2011011529A (es) 2012-02-08
HRP20131070T1 (hr) 2013-12-20
EP2424538B1 (en) 2013-08-14
PL2424538T3 (pl) 2014-05-30
BRPI1011971A2 (pt) 2016-04-26
DK2424538T3 (da) 2013-11-04
IL215831A0 (en) 2012-01-31
ME01567B (me) 2014-04-20
PT2424538E (pt) 2013-11-07
KR20120049848A (ko) 2012-05-17
EP2424538A1 (en) 2012-03-07
RS53005B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
AR124134A2 (es) Formulación de uso tópico para un inhibidor de jak
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CL2011000710A1 (es) Combinacion farmaceutica que comprende un inhibidor especifico de smoothened y un inhibidor de cinasa pi3 especifico; y uso en el tratamiento de cancer.
PE20120371A1 (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak
CY1110336T1 (el) Χρηση της αλλοπουρινολης για τη θεραπεια της παλαμοπελματικης ερυθροδυσαισθησιας
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
AR076505A1 (es) Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
ECSP10010553A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
ECSP077843A (es) Tratamiento o prevención del prurito
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
UY31790A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona
BR112015010223A2 (pt) compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
AR108792A1 (es) Composiciones que comprenden timolol
TN2013000336A1 (en) 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.
AR078798A1 (es) Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona
CU20100004A7 (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k

Legal Events

Date Code Title Description
FB Suspension of granting procedure